专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013040164A1 COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS 审中-公开
标题翻译：用于治疗代谢障碍的组合物和方法
公开(公告)号：WO2013040164A1
公开(公告)日：2013-03-21
申请号：PCT/US2012/055088
申请日：2012-09-13
申请人： BIOMED VALLEY DISCOVERIES, INC. , HALSE, Reza , ROIX, Jeffrey James , SAHA, Saurabh
发明人： HALSE, Reza , ROIX, Jeffrey James , SAHA, Saurabh
IPC分类号： A61K31/40 , C07D207/08
CPC分类号： A61K31/40 , A61K31/4985 , A61K2300/00
摘要： The present invention provides, inter alia, compositions containing enantiomerically pure (R)(+)-amisulpride or enantiomerically pure (R)(+)-sulpiride, optionally with dopamine receptor modulators. The present invention also provides compositions containing racemic (RS)-amisulpride or (RS)-sulpiride in combination with dopamine receptor modulators. Methods for preventing, treating, or ameliorating the effects of a metabolic disorder or key element thereof, for modulating blood glucose levels, and for preventing, treating, or ameliorating the effects of diabetes in a subject are also provided. Additionally, the present invention provides methods for counter-acting the dopamine antagonist activity of (S)-amisulpride in racemic (RS)-amisulpride, or the dopamine antagonist activity of (S)-sulpiride in racemic (RS)-sulpiride, administered to a subject to prevent, treat, or ameliorate the effects of a metabolic disorder.
摘要翻译：本发明尤其提供含有对映异构纯的（R）（+） - 氨磺酸或对映体纯的（R）（+） - 舒必利，任选与多巴胺受体调节剂组合的组合物。本发明还提供了与多巴胺受体调节剂组合含有外消旋（RS） - 马可福酯或（RS）-Sulpiride的组合物。还提供了用于预防，治疗或改善代谢紊乱或其关键要素的作用，用于调节血糖水平以及预防，治疗或改善受试者中糖尿病的作用的方法。另外，本发明提供了在外消旋（RS） - 米沙夫定反作用（S） - 阿米替丁的多巴胺拮抗剂活性或外消旋（RS）-Sulpiride中（S）-Sulpiride的多巴胺拮抗剂活性的方法）预防，治疗或改善代谢紊乱的影响的主题。

2. 发明申请

WO2015095819A2 CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS 审中-公开
标题翻译：用ERK和RAF抑制剂联合治疗癌症
公开(公告)号：WO2015095819A2
公开(公告)日：2015-06-25
申请号：PCT/US2014/071715
申请日：2014-12-19
申请人： BIOMED VALLEY DISCOVERIES, INC.
发明人： SAHA, Saurabh , WELSCH, Dean , DECRESCENZO, Gary , ROIX, Jeffrey James
IPC分类号： A61K31/525 , A61K39/395
CPC分类号： A61K31/4439 , A61K31/428 , A61K31/437 , A61K31/44 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/555 , A61K45/06 , A61K2300/00
摘要： The present invention provides, inter alia , methods of treating or ameliorating the effects of a cancer in a subject. The methods include administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a type 1 RAF inhibitor (such as dabrafenib) or another RAF inhibitor (such as regorafenib) or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Also provided are pharmaceutical compositions and kits for treating or ameliorating the effects of a cancer in a subject.
摘要翻译：本发明提供了治疗或改善受试者中癌症的效果的方法，尤其是提供了一种方法。该方法包括向受试者施用有效量的（i）第一抗癌剂，其是BVD-523或其药学上可接受的盐，和（ii）第二种抗癌剂，其是1型RAF抑制剂（如达拉菲尼）或另一种RAF抑制剂（如瑞格非尼）或其药学上可接受的盐，以治疗或改善癌症的效果。还提供了用于治疗或改善受试者中癌症的作用的药物组合物和试剂盒。

3. 发明申请

WO2014209804A1 BISPECIFIC ANTIBODIES 审中-公开
标题翻译：双重抗体
公开(公告)号：WO2014209804A1
公开(公告)日：2014-12-31
申请号：PCT/US2014/043480
申请日：2014-06-20
申请人： BIOMED VALLEY DISCOVERIES, INC.
发明人： SAHA, Saurabh , ROIX, Jeffrey James , WELSCH, Dean
IPC分类号： C07K16/28
CPC分类号： C07K16/468 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/2803 , C07K16/2818 , C07K16/30 , C07K16/3023 , C07K16/3038 , C07K2317/21 , C07K2317/31 , C07K2317/35 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/76
摘要： The present invention provides, inter alia , bispecific antibodies containing a first antigen binding moiety that specifically binds an epitope on human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and a second antigen binding moiety that specifically binds an epitope on a human programmed death 1 (PD-1) receptor. Also provided are pharmaceutical compositions containing such bispecific antibodies, as well as methods and kits for treating cancer using such bispecific antibodies and pharmaceutical compositions.
摘要翻译：本发明特别提供了包含特异性结合人细胞毒性T淋巴细胞相关抗原4（CTLA-4）上的表位的第一抗原结合部分和特异性结合人的表位的第二抗原结合部分的双特异性抗体程序死亡1（PD-1）受体。还提供含有这种双特异性抗体的药物组合物，以及使用这种双特异性抗体和药物组合物治疗癌症的方法和试剂盒。

4. 发明申请

WO2017201532A1 METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS 审中-公开
标题翻译：治疗非ERK MAPK途径抑制剂抗癌的方法和组合物
公开(公告)号：WO2017201532A1
公开(公告)日：2017-11-23
申请号：PCT/US2017/033843
申请日：2017-05-22
申请人： BIOMED VALLEY DISCOVERIES, INC.
发明人： SAHA, Saurabh , WELSCH, Dean , DECRESCENZO, Gary , ROIX, Jeffrey James
IPC分类号： A61K31/4439 , A61K31/675 , A61P9/10 , A61P31/12 , A61P37/04 , A61P37/06
摘要： The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy. Also provided are methods for identifying a subject having cancer who would benefit from therapy with an ERK inhibitor and methods for inhibiting phosphorylation of RSK in a cancer cell that is refractory or resistant to a non-ERK MAPK pathway inhibitor.
摘要翻译：本发明特别提供用于治疗或改善受试者中癌症效应的方法，药物组合物和试剂盒，所述癌症对于非ERK MAPK途径抑制剂治疗。还提供了用于鉴定将受益于ERK抑制剂治疗的具有癌症的受试者的方法，以及抑制对非ERK MAPK途径抑制剂具有难治性或抗性的癌细胞中RSK磷酸化的方法。

5. 发明申请

WO2015095833A1 TREATMENT OF HEMATOLOGIC CANCERS 审中-公开
标题翻译：治疗肝癌
公开(公告)号：WO2015095833A1
公开(公告)日：2015-06-25
申请号：PCT/US2014/071733
申请日：2014-12-19
申请人： BIOMED VALLEY DISCOVERIES, INC.
发明人： SAHA, Saurabh , WELSCH, Dean , DECRESCENZO, Gary , ROIX, Jeffrey James
IPC分类号： A61P35/02
CPC分类号： A61K45/06 , A61K31/4439 , A61K31/506 , A61K31/519 , A61K2300/00
摘要： The present invention provides, inter alia , methods of treating or ameliorating the effects of a hematologic cancer in a subject in need of such treatment. These methods include administering to the subject an effective amount of an ERK1/2 inhibitor, such as BVD-523, to treat or ameliorate the effects of the hematologic cancer. Also provided are methods of modulating ribosomal S6 kinase (RSK) phosphorylation in the blood of a subject that has a hematologic cancer. Pharmaceutical compositions and kits for treating or ameliorating the effects of a hematologic cancer are additionally provided.
摘要翻译：本发明尤其提供了在需要这种治疗的对象中治疗或改善血液癌症的作用的方法。这些方法包括向受试者施用有效量的ERK1 / 2抑制剂，例如BVD-523，以治疗或改善血液癌的作用。还提供了在具有血液癌症的受试者的血液中调节核糖体S6激酶（RSK）磷酸化的方法。还提供用于治疗或改善血液癌症的作用的药物组合物和试剂盒。

6. 发明申请

WO2015095842A2 METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS 审中-公开
标题翻译：治疗非ERK MAPK途径抑制剂抗癌的方法和组合物
公开(公告)号：WO2015095842A2
公开(公告)日：2015-06-25
申请号：PCT/US2014/071749
申请日：2014-12-19
申请人： BIOMED VALLEY DISCOVERIES, INC.
发明人： SAHA, Saurabh , WELSCH, Dean , DECRESCENZO, Gary , ROIX, Jeffrey James
IPC分类号： A61K31/498
CPC分类号： A61K31/4439 , A61K31/506 , A61K31/519 , A61K45/06 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , G01N33/57484 , A61K2300/00
摘要： The present invention provides, inter alia , methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy. Also provided are methods for identifying a subject having cancer who would benefit from therapy with an ERK inhibitor and methods for inhibiting phosphorylation of RSK in a cancer cell that is refractory or resistant to a non-ERK MAPK pathway inhibitor.
摘要翻译：本发明提供了用于治疗或改善受试者中癌症的效果的方法，药物组合物和试剂盒，所述癌症耐受或耐受非ERK MAPK途径抑制剂治疗。还提供了用于鉴定将受益于ERK抑制剂治疗的具有癌症的受试者的方法，以及抑制对非ERK MAPK途径抑制剂具有难治性或抗性的癌细胞中RSK磷酸化的方法。

7. 发明申请

WO2015095838A2 CANCER TREATMENTS USING COMBINATIONS OF MEK TYPE I AND ERK INHIBITORS 审中-公开
标题翻译：使用MEK I型和ERK抑制剂组合的癌症治疗
公开(公告)号：WO2015095838A2
公开(公告)日：2015-06-25
申请号：PCT/US2014/071744
申请日：2014-12-19
申请人： BIOMED VALLEY DISCOVERIES, INC.
发明人： SAHA, Saurabh , DECRESCENZO, Gary , ROIX, Jeffrey James
IPC分类号： A61K31/498
CPC分类号： A61K31/4439 , A61K31/365 , A61K31/5377 , A61K45/06 , A61K2300/00
摘要： The present invention provides, inter alia , methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method comprises administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a type 1 MEK inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.
摘要翻译：本发明尤其提供用于治疗或改善有需要的受试者中癌症的作用的方法，试剂盒和药物组合物。该方法包括向受试者施用有效量的（i）第一抗癌剂，其为BVD-523或其药学上可接受的盐，和（ii）第二种抗癌剂，其为1型MEK抑制剂或其药学上可接受的盐，以治疗或改善癌症的作用。还提供了用于实现癌细胞死亡的其它方法。

8. 发明申请

WO2015095825A1 CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS 审中-公开
标题翻译：使用2型MEK和ERK抑制剂组合的癌症治疗
公开(公告)号：WO2015095825A1
公开(公告)日：2015-06-25
申请号：PCT/US2014/071724
申请日：2014-12-19
申请人： BIOMED VALLEY DISCOVERIES, INC.
发明人： SAHA, Saurabh , WELSCH, Dean , DECRESCENZO, Gary , ROIX, Jeffrey James
IPC分类号： A61K31/00
CPC分类号： A61K31/4439 , A61K31/337 , A61K31/4184 , A61K31/437 , A61K31/506 , A61K31/519 , A61K45/06 , A61K2300/00
摘要： The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method includes administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD 523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a type 2 MEK inhibitor, or other MEK inhibitors, or pharmaceutically acceptable salts thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.
摘要翻译：本发明尤其提供用于治疗或改善有需要的受试者中癌症的作用的方法，试剂盒和药物组合物。该方法包括向受试者施用有效量的（i）第一抗癌剂，其为BVD 523或其药学上可接受的盐，和（ii）第二种抗癌剂，其为2型MEK抑制剂，或其他MEK抑制剂或其药学上可接受的盐，以治疗或改善癌症的作用。还提供了用于实现癌细胞死亡的其它方法。

9. 发明申请

WO2015095840A1 CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS 审中-公开
标题翻译：使用CDK和ERK抑制剂组合的癌症治疗
公开(公告)号：WO2015095840A1
公开(公告)日：2015-06-25
申请号：PCT/US2014/071747
申请日：2014-12-19
申请人： BIOMED VALLEY DISCOVERIES, INC.
发明人： SAHA, Saurabh , WELSCH, Dean , DECRESCENZO, Gary , ROIX, Jeffrey James
IPC分类号： A01N43/40 , C07D401/00
CPC分类号： A61K31/519 , A61K31/4439 , A61K31/506 , A61K45/06 , C07D401/04 , A61K2300/00
摘要： The present invention provides, inter alia , methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method comprises administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.
摘要翻译：本发明尤其提供用于治疗或改善有需要的受试者中癌症的作用的方法，试剂盒和药物组合物。该方法包括向受试者施用有效量的（i）第一抗癌剂，其为BVD-523或其药学上可接受的盐，和（ii）第二种抗癌剂，其为CDK抑制剂或其药学上可接受的盐，以治疗或改善癌症的作用。还提供了用于实现癌细胞死亡的其它方法。

10. 发明申请

WO2015095831A1 CANCER TREATMENTS USING COMBINATIONS OF MTOR AND ERK INHIBITORS 审中-公开
标题翻译：癌症治疗使用MTOR和ERK抑制剂的组合
公开(公告)号：WO2015095831A1
公开(公告)日：2015-06-25
申请号：PCT/US2014/071731
申请日：2014-12-19
申请人： BIOMED VALLEY DISCOVERIES, INC.
发明人： SAHA, Saurabh , WELSCH, Dean , DECRESCENZO, Gary , ROIX, Jeffrey James
IPC分类号： A61K31/4439
CPC分类号： A61K31/4439 , A61K31/436 , A61K31/4745 , A61K31/506 , A61K31/5377 , A61K45/06 , A61K2300/00
摘要： The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method comprises administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a mTOR inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.
摘要翻译：本发明尤其提供用于治疗或改善有需要的受试者中癌症的作用的方法，试剂盒和药物组合物。该方法包括向受试者施用有效量的（i）第一抗癌剂，其为BVD-523或其药学上可接受的盐，和（ii）第二种抗癌剂，其为mTOR抑制剂或其药学上可接受的盐，以治疗或改善癌症的作用。还提供了用于实现癌细胞死亡的其它方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式